RecruitingPhase 1NCT07310420
A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
Sponsor: TerSera Therapeutics LLC
Bethlehem, PA · Sayre, PA · +24 more sites